Compare AbbVie Inc (ABBV) vs Fox Corp Class A (FOXA) Price & Performance

AbbVie IncTrade

Fox Corp Class ATrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Fox Corp Class A — how do they compare? AbbVie Inc trades at $247.74 (market cap $438.19B), while Fox Corp Class A trades at $63.45 (market cap $25.05B). The key difference: AbbVie Inc is far larger — about 17.5× Fox Corp Class A's market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.

	ABBV	FOXA
Market Cap	$438.19B	$25.05B
Sector	Health	Media
52-Week High	$263.58	$76.11
52-Week Low	$197.38	$48.79
Enterprise Value	$502.45B	$28.41B
Dividend Yield	2.79%	0.91%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $246.04, up 0.89% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats and robust revenue growth driven by Skyrizi and Rinvoq offset Humira declines, though net margins have compressed. The stock is supported by a solid dividend and institutional accumulation.

Outlook remains positive with a consensus price target of $281.33, but risks include patent cliffs in the 2030s and high debt levels. Revenue growth and pipeline advancements provide upside, yet valuation metrics like a P/E of 69.5 suggest premium pricing relative to earnings.

Fox Corp Class A

FOXA trades at $64.03, up 3.63% on strong Q4 2026 earnings beats driven by World Cup advertising and Tubi streaming growth. The stock shows bullish technical momentum with a consensus price target of $65.33, supported by a 50% buy rating from analysts. Revenue grew to $16.30B in 2025, with net income margin expanding to 13.88%, though 2026 projections indicate moderation.

Outlook remains positive with digital ad momentum and strategic initiatives, but risks include sports cost pressures and cyclical advertising dependence. The current valuation at a P/E of 16.52 appears reasonable relative to earnings growth, offering potential upside if execution continues.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 1 day agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 1 day agoBullish Nxera Pharma reports Q2 2026 profit on milestone payments and advances in drug development.Nxera Pharma · 4 days agoBullish View details →

FOXA

FIFA World Cup boosts Fox's revenue 28%, ad sales surge 78% driven by big viewership and streaming growthCNBC · 5 days agoBullish View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About Fox Corp Class A

Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.